Literature DB >> 18093649

Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality.

Rebecca Fransson1, Milad Botros, Fred Nyberg, Gunnar Lindeberg, Anja Sandström, Mathias Hallberg.   

Abstract

Some of the biological effects demonstrated after administration of substance P (SP) in vivo can indirectly be attributed to the fragmentation of the undecapeptide to its N-terminal bioactive fragment SP(1-7). This heptapeptide (H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH) is a major bioactive metabolite from SP that frequently exerts similar biological effects as the parent peptide but also, in several cases, completely opposite actions. Specific binding sites for the heptapeptide SP(1-7) that are separate from the SP preferred NK receptors have been identified. In this study we demonstrate that (a) the C-terminal part of the SP metabolite SP(1-7) is most important for binding as deduced from an Ala scan and that a replacement of Phe(7) for Ala is deleterious, (b) truncation of the N-terminal amino acid residues of SP(1-7) delivers peptides with retained binding activity, although with somewhat lower binding affinities than SP(1-7) and (c) a C-terminal amide group as a replacement for the terminal carboxy group of SP(1-7) and for all of the truncated ligands synthesized affords approximately 5-10-fold improvements of the binding affinities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18093649     DOI: 10.1016/j.npep.2007.11.002

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  6 in total

1.  Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.

Authors:  Rebecca Fransson; Gunnar Nordvall; Johan Bylund; Anna Carlsson-Jonsson; Jadel M Kratz; Richard Svensson; Per Artursson; Mathias Hallberg; Anja Sandström
Journal:  ACS Med Chem Lett       Date:  2014-10-29       Impact factor: 4.345

2.  The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system.

Authors:  Masahiro Ohsawa; Anna Carlsson; Megumi Asato; Takayuki Koizumi; Yuki Nakanishi; Rebecca Fransson; Anja Sandström; Mathias Hallberg; Fred Nyberg; Junzo Kamei
Journal:  Mol Pain       Date:  2011-10-31       Impact factor: 3.395

3.  Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists.

Authors:  Silvana Vasile; Anders Hallberg; Jessica Sallander; Mathias Hallberg; Johan Åqvist; Hugo Gutiérrez-de-Terán
Journal:  Biomolecules       Date:  2020-04-23

4.  The effect of substance P and its common in vivo-formed metabolites on MRGPRX2 and human mast cell activation.

Authors:  Lin Hsin; Nithya A Fernandopulle; Jie Ding; Chris Lumb; Nicholas Veldhuis; John A Karas; Susan E Northfield; Graham A Mackay
Journal:  Pharmacol Res Perspect       Date:  2022-08

5.  Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P1-7.

Authors:  Aleksandra Pekošak; Janez Ž Bulc; Špela Korat; Robert C Schuit; Esther Kooijman; Ricardo Vos; Marissa Rongen; Mariska Verlaan; Kevin Takkenkamp; Wissam Beaino; Alex J Poot; Albert D Windhorst
Journal:  Mol Pharm       Date:  2018-10-25       Impact factor: 4.939

Review 6.  From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase.

Authors:  Mathias Hallberg; Mats Larhed
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.